This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Conceptus® Reports First Quarter Sales Of $33.4 Million

Cash, cash equivalents and investments were $99.3 million as of March 31, 2010, a decrease of $5.9 million from December 31, 2009. In the first quarter of 2010 the Company repaid $3.6 million of its outstanding short-term loan balance with UBS Financial Services.

Financial Guidance

Conceptus also announced financial guidance for second quarter of 2010, and affirmed full year 2010 net sales and net income guidance, as follows:
  • The Company expects net sales in the second quarter to be in the range of $39.5 million to $41.0 million, and affirms guidance for net sales for the full year to be in the range of $160.0 million to $165.0 million.
  • The Company expects second quarter GAAP diluted EPS to be in the range of $0.00 to $0.03, and non-GAAP diluted EPS to be in the range of $0.12 to $0.15, based on 32.2 million weighted average shares outstanding.
  • The Company affirms guidance for full year GAAP earnings to be in the range of $0.50 to $0.55 per diluted share, and for full year non-GAAP earnings to be in the range of $0.99 to $1.04 per diluted share.

“We are pleased to have exceeded our earnings guidance for the first quarter of 2010,” commented Mark Sieczkarek, president and chief executive officer of Conceptus. “As we expected, lingering unemployment and a broad-based decrease in physician office visits in the first quarter of 2010 slowed our growth, but this environment in no way detracts from our enthusiasm for the long-term growth potential of the Essure procedure. We remain cautious in our macroeconomic outlook for the remainder of 2010, yet are optimistic that our company-specific awareness initiatives will continue to support increased usage of the Essure procedure.”

These statements are only effective as of the date of this press release and Conceptus undertakes no duty to publicly revise or update these forward-looking statements, whether as a result of new information, future developments or otherwise.

2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $110.32 -0.89%
FB $92.47 -0.36%
GOOG $639.40 -0.94%
TSLA $234.02 -3.10%
YHOO $31.68 2.30%


Chart of I:DJI
DOW 16,868.06 +77.87 0.46%
S&P 500 1,990.38 +10.46 0.53%
NASDAQ 4,772.20 +23.8390 0.50%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs